ALAMEDA, Calif., Nov. 4, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (NasdaqGM:AVGN - News), a biopharmaceutical company innovating therapies for the treatment of chronic neurological conditions, today announced the company presented data from a Phase I study of one of its leading pipeline products, AV650 (tolperisone HCl), at the 37th annual meeting of the Society for Neuroscience (SfN) on November 4, 2007 at the San Diego Convention Center in San Diego, California. This Phase I data showed AV650 to be well tolerated with no evidence of sedation.
